Replies to post #79290 on NorthWest Biotherapeutics Inc (NWBO)

[doingmybest]

What do you think is a reasonable prediction of time to see top line data if Nov is the end of the primary data collection is Nov? I am thinking Jan. I am wondering how long they still have to cover expenses with such a low sp. And, since the first and most important domino is the P3 results, all else can start to happen after.

So, does Jan disclosure seem realistic to you and all for such a study? The number of patients is modest but the analysis is deep, though maybe not so for top line.

I am also wondering if they will want to have an agency discussion prior to disclosure under the circumstances, which we still do not yet understand regarding the partial clinical (screening) hold?

[md1225]

I agree

[HappyLibrarian]

We'll see but if I had $100 for every time I've heard talk of a "big gap up" that never comes I would not be in the red on my NWBO investment.

If the trial truly ends in November 2016, NWBO needs to say so, at the time it happens and they can always say analysis will take X amount of time.

But we at least need to know that the fight is over and the referees are going over the cards.

That much they can do and should do because first because it is time for them to do right by shareholders and second, because financially, it might raise the price enough to allow one last financing at a higher level before the moment of truth arrives.

A lot of people will want to load up on spec (buy on rumor and sell on news) and I don't think even short interests (assuming they are even involved) could suppress that kind of price move. Attenuate it?

Sure, but NWBO will still get a higher price for financing if people know for a fact that we are going to get resolution, for good and all on Phase 3 very shortly.